【英語タイトル】Liquid Biopsy Market Forecasts to 2032 - Global Analysis By Product Type (Assay Kits & Reagents, Instruments, Services, and Other Product Types), Biomarker Type, Sample Type, Technology, Application, End User and By Geography
	・商品コード：SMRC8892CW227 ・発行会社（調査会社）：Stratistics MRC ・発行日：2025年2月 ・ページ数：約150 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル ・産業分野：バイオ

According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $13447.02 million in 2025 and is expected to reach $32628.51 million by 2032 growing at a CAGR of 13.5% during the forecast period. Liquid biopsy is a non-invasive diagnostic technique that detects cancer and other diseases by analyzing biomarkers such as circulating tumor DNA (ctDNA), RNA, or exosomes present in body fluids like blood or urine. It offers a real-time snapshot of disease progression, enabling early detection, monitoring of treatment response, and detection of recurrence. Liquid biopsy provides a safer, quicker alternative to traditional tissue biopsies, enhancing patient care and personalized treatment strategies.

According to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected in 2023.

Market Dynamics:

Driver:

Increased preference for personalized medicine

The growing shift toward personalized medicine is a major catalyst for the expansion of the liquid biopsy market. As oncology care becomes more tailored, clinicians increasingly rely on minimally invasive tools like liquid biopsy to guide treatment decisions. These tests enable real-time monitoring of tumor dynamics, helping physicians adjust therapies based on individual molecular profiles. The ability to detect actionable mutations through circulating biomarkers supports the use of targeted therapies, improving patient outcomes. This rising demand for precision diagnostics is accelerating the adoption of liquid biopsy across research and clinical settings.

Restraint:

Limited clinical validation

Many liquid biopsy tests, particularly those detecting early-stage cancers or rare mutations, lack comprehensive, large-scale clinical trials to confirm their sensitivity, specificity, and overall reliability. Without robust validation, healthcare providers may hesitate to trust these tests for critical decisions such as diagnosis, treatment planning, or monitoring. This uncertainty also impacts regulatory approvals and insurance reimbursements, further delaying market penetration. To gain broader acceptance, more longitudinal studies and peer-reviewed evidence are essential to establish clinical utility across diverse patient populations.

Opportunity:

Advancements in genomics and next-generation sequencing (NGS)

NGS technologies enable high-throughput, accurate, and cost-effective analysis of circulating tumor DNA (ctDNA), exosomes, and other biomarkers from blood samples. These innovations allow for the detection of genetic mutations, copy number variations, and epigenetic changes with unprecedented sensitivity and specificity. As NGS becomes more accessible and integrated into clinical workflows, it enhances the ability to diagnose cancer early, monitor disease progression, and guide personalized treatment. Continuous improvements in sequencing speed, data analytics, and bioinformatics are further accelerating the clinical adoption of liquid biopsy.

Threat:

Complexity in data interpretation

The increasing complexity of genomic data generated by liquid biopsy tests poses a significant challenge. Interpreting multi-gene panels and distinguishing clinically relevant mutations from benign variants requires advanced bioinformatics expertise. Inconsistent reporting standards and lack of consensus on variant classification can lead to confusion among clinicians. This complexity may delay treatment decisions or result in suboptimal therapy selection. Smaller labs and healthcare providers may lack the infrastructure to manage and analyze such data effectively. Without streamlined interpretation tools and standardized guidelines, the full potential of liquid biopsy may remain underutilized.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the liquid biopsy market. Initially, diagnostic delays and reduced hospital visits led to a temporary decline in cancer screening and monitoring procedures. However, the need for non-invasive, remote-friendly testing solutions brought renewed attention to liquid biopsy. As healthcare systems adapted, liquid biopsy emerged as a safer alternative to tissue biopsies, especially for immunocompromised patients. Post-pandemic, the market witnessed accelerated adoption driven by increased awareness of early detection and real-time monitoring.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, due to the critical role of platforms such as NGS systems, digital PCR, and microfluidic devices in enabling accurate biomarker detection. These instruments form the backbone of liquid biopsy workflows, supporting both research and clinical applications. Continuous innovation in sequencing speed, throughput, and automation is enhancing test efficiency and scalability. As demand for high-sensitivity diagnostics grows, investment in advanced instrumentation is expected to rise.

The specialty clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate. These clinics are increasingly adopting liquid biopsy for cancer screening, therapy selection, and recurrence monitoring. Their focused expertise and streamlined workflows make them ideal settings for implementing advanced diagnostics. As awareness of personalized medicine grows, patients are turning to specialty centers for tailored care. Additionally, partnerships between diagnostic companies and specialty clinics are expanding access to cutting-edge tests.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing government investment in precision medicine. Countries like China, India, and Japan are witnessing rapid adoption of advanced diagnostics, including liquid biopsy. Local players are also entering the market with cost-effective solutions tailored to regional needs. Public-private partnerships and favorable regulatory reforms are further accelerating market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region benefits from a well-established healthcare system, strong R&D ecosystem, and early adoption of genomic technologies. Regulatory approvals for liquid biopsy-based companion diagnostics are increasing, boosting clinical confidence. Additionally, rising demand for non-invasive cancer screening and monitoring is fueling test volumes. Strategic collaborations between biotech firms, academic institutions, and healthcare providers are driving innovation.

Key players in the market

Some of the key players in Liquid Biopsy Market include F. Hoffmann-La Roche Ltd., Menarini Silicon Biosystems, Guardant Health Inc., Freenome Holdings, Inc., Illumina Inc., Biocept, Inc., Thermo Fisher Scientific Inc., ANGLE plc, Exact Sciences Corporation, Caris Life Sciences, Natera Inc., NeoGenomics Laboratories, QIAGEN N.V., Lucence Health Inc., Bio-Rad Laboratories Inc., Foundation Medicine, Inc., Epigenomics AG, Johnson & Johnson Services Inc., Myriad Genetics, Inc., and Sysmex Corporation.

Key Developments:

In May 2025, Roche announced a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab’s research community.

In July 2022, Menarini Silicon Biosystems Inc, announced at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.

Product Types Covered:
• Assay Kits & Reagents
• Instruments
• Services
• Other Product Types

Biomarker Types Covered:
• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Exosomes and Extracellular Vesicles
• Cell-Free DNA (cfDNA)
• Cell-Free RNA (cfRNA)
• Circulating Proteins
• Other Biomarker Types

Sample Types Covered:
• Blood
• Saliva
• Urine
• Fecal-Based Sampling
• Other Body Fluids

Technologies Covered:
• Next-Generation Sequencing (NGS)
• Beads, Emulsion, Amplification, and Magnetics (BEAMing)
• Polymerase Chain Reaction (PCR)
• Digital Droplet PCR (ddPCR)
• Other Technologies

Applications Covered:
• Cancer Applications
• Non-Cancer Applications
• Other Applications

End Users Covered:
• Hospitals and Physician Laboratories
• Diagnostic Laboratories
• Academic and Research Institutes
• Biopharmaceutical and Biotechnology Companies
• Reference Laboratories
• Specialty Clinics
• Other End Users